Androgen Suppression Tx May Prevent Intravesical Recurrence

Share this content:
Androgen Suppression Tx May Prevent Intravesical Recurrence
Androgen Suppression Tx May Prevent Intravesical Recurrence

FRIDAY, Jan. 20, 2017 (HealthDay News) -- For men with bladder cancer, androgen suppression therapy may be prophylactic for intravesical recurrence, according to a study published in the February issue of The Journal of Urology.

Masaki Shiota, M.D., Ph.D., from Kyushu University in Fukuoka, Japan, and colleagues examined whether intravesical recurrence is affected by inhibition of androgen signaling in men with non-muscle invasive bladder cancer. Data were included for 228 men (32 with and 196 without androgen suppression therapy) receiving androgen deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia.

The researchers found that intravesical recurrence developed in 12.5 and 30.1 percent of men with and without androgen suppression therapy during a median follow-up of 3.6 and 3.0 years, respectively. Independent significant risk factors for intravesical recurrence on multivariate analysis included multiple tumors, a large tumor, and ever smoking (hazard ratios, 1.82, 2.13, and 2.45, respectively), as well as presence of androgen suppression therapy (hazard ratio, 0.36). In 3.1 percent of men without androgen suppression therapy, tumor progressed to muscle invasive bladder cancer, compared with none of the men with androgen suppression therapy.

"Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer," the authors write. "Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis."

The study was supported by the Takeda Science Foundation Medical Research Promotion Grant and the Daiwa Securities Health Foundation.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »